The canadian market potential is 10 million doses
Even though the initial number of small pox vaccines bought by the Canadian government is relatively small the potential is great – and Europe could be right around the corner.
by Henrik Tüchsen
Canada has just bought 20,000 doses of Bavarian Nordic’s vaccine with an option to buy an additional 180,000, but the market potential for the country is 10 million doses, Bavarian CEO Anders Hedegaard tells Medwatch. Meanwhile, the company has begun negotiations with a number of other countries, and they hope to start delivering the vaccine to European countries in the near future.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
- Adgang til alle låste artikler
- Modtag vores daglige nyhedsbreve
- Fuld adgang til vores app
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler:
Bavarian wins order and raises expectations
For abonnenter
.jpg&w=384&q=75){kind=logo}
